Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study.<\/b>\u00a0 Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, et al. Journal of Perinatology. 2022;<\/p>\n
Abstract<\/p>\n
Objective:<\/b> To compare short-term respiratory outcomes in preterm infants treated with bovine lipid extract surfactant or poractant alfa.<\/p>\n
Study design:<\/b> Prospective comparative effectiveness cohort study of infants <32 weeks’ gestational age requiring surfactant in thirteen centers. Each center provided bovine lipid extract surfactant for a set period of time in the year 2019 and then changed to poractant alfa for the remainder of the year. The primary outcome was total duration of respiratory support.<\/p>\n
Result: <\/b>968 infants were included. 494 received bovine lipid extract surfactant and 474 received poractant alfa. No difference was observed in the total duration of respiratory support (mechanical ventilation or non-invasive) (median 38 vs 40.5 days), need to re-dose surfactant, bronchopulmonary dysplasia, survival to discharge, or length of admission.<\/p>\n
Conclusion: <\/b>In this pragmatic study, we did not identify any difference in short-term outcomes between the groups based on the type of surfactant received.<\/p>\n
1. Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, et al. Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study. Journal of Perinatology. 2022;<\/p>\n